EVENTS | VIEW CALENDAR
WuXi NextCODE taps N-of-One for global agreement
LEXINGTON, Mass.—N-of-One Inc. and WuXi NextCODE have inked a global agreement under which N-of-One will provide clinical and scientific evidence for delivering the best personalized treatment options based on the results of WuXi NextCODE tumor- normal genome sequence interpretation. N-of-One's clinical interpretation provides evidence related to the mutational profile of a tumor identified by sequencing, while taking into account each patient's specific molecular profile. It also links that clinical and scientific evidence to therapeutic strategies relevant for each patient. No financial terms for the agreement were disclosed.
“N-of-One is very pleased to be working closely with WuXi NextCODE to deliver a best-in-class, patient-specific solution to the market,” Chris Cournoyer, CEO of N-of- One, said in press release. “Our objective is to continue to provide high-quality, patient-specific clinical interpretation evidence at a cost- effective price and through our partnership with WuXi to extend our reach globally.”
This agreement will enable N-of-One and WuXi NextCODE to collaborate on the latter's work with the UK 100,000 Genomes Project and tailor offerings for other geographies in the future.
“We are very pleased to be able to offer N-of-One solutions to our cancer diagnostics partners,” commented Hannes Smarason, co-founder, president and chief operating officer of WuXi NextCODE. “Through our work in China, the US and Europe we are making it possible to efficiently identify the molecular drivers of individual tumors, and N-of-One provides the latest scientific and clinical evidence to enable clinicians to find the treatments best suited to each patient.”
WuXi NextCODE announced another partnership the next day with the news that it had contracted with Genomics England for the 100,000 Genomes Project. The goal of this initiative is to sequence 100,000 whole genomes from approximately 70,000 people, with participants consisting of NHS patients with a rare disease, plus their families, and patients with cancer. It is hoped this will enable the creation of anew genomic medicine service for the NHS and more personalized care for patients.
WuXi NextCODE is the first to work with Genomics England on cancer samples, and will also interpret rare diseases samples. Genomics England will collaborate with the clinical interpretation partners to increase the quality of interpretation of genomic data.
Hannes Smarason, President and COO of WuXi NextCODE, a wholly owned subsidiary of WuXi AppTec, said: "We are very pleased to be playing a central role in a project that is a driving force for precision medicine worldwide. We look forward to putting our technology to work for NHS patients through interpretation and by applying the knowledge gained to advance the development of targeted new therapies for cancer and a range of rare conditions."